Profound Medical (NASDAQ:PROF) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Profound Medical from “sell” to “hold.” Overall analyst sentiment is more favorable, with a “Moderate Buy” consensus and an average target price of $11.50.
• Profound Medical reported weaker-than-expected quarterly results, including an adjusted loss of $0.26 per share versus estimates of $0.22 and revenue of $2.48 million versus expectations of $4.75 million.
• The stock opened at $6.90, with a market capitalization of approximately $252 million, while institutional investors owned 47.86% of outstanding shares.

Profound Medical (NASDAQ:PROF - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday, Wall Street Zen reports.

Other equities analysts have also issued reports about the company. Raymond James Financial upgraded Profound Medical from an "outperform" rating to a "strong-buy" rating and set a $11.00 target price for the company in a research report on Monday, July 27th. Weiss Ratings raised shares of Profound Medical from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Profound Medical has an average rating of "Moderate Buy" and a consensus target price of $11.50.

Profound Medical Stock Down 0.1%

NASDAQ:PROF opened at $6.90 on Friday. Profound Medical has a 12-month low of $4.80 and a 12-month high of $8.95. The firm has a market capitalization of $252.26 million, a P/E ratio of -7.04 and a beta of 0.75. The stock's fifty day simple moving average is $6.57 and its 200-day simple moving average is $6.69.

Profound Medical (NASDAQ:PROF - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.04). Profound Medical had a negative net margin of 171.57% and a negative return on equity of 63.03%. The company had revenue of $2.48 million during the quarter, compared to the consensus estimate of $4.75 million. As a group, equities research analysts expect that Profound Medical will post -0.81 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PROF. Gagnon Securities LLC increased its holdings in shares of Profound Medical by 12.2% in the fourth quarter. Gagnon Securities LLC now owns 1,944,061 shares of the company's stock worth $15,300,000 after acquiring an additional 211,021 shares in the last quarter. Ardsley Advisory Partners LP lifted its holdings in shares of Profound Medical by 36.4% during the 4th quarter. Ardsley Advisory Partners LP now owns 450,000 shares of the company's stock valued at $3,542,000 after purchasing an additional 120,000 shares in the last quarter. Connective Capital Management LLC bought a new position in shares of Profound Medical during the 4th quarter valued at about $787,000. Gagnon Advisors LLC grew its position in shares of Profound Medical by 7.3% in the 4th quarter. Gagnon Advisors LLC now owns 962,186 shares of the company's stock valued at $7,572,000 after purchasing an additional 65,515 shares during the period. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Profound Medical in the 1st quarter valued at approximately $259,000. 47.86% of the stock is currently owned by institutional investors.

More Profound Medical News

Here are the key news stories impacting Profound Medical this week:

• Positive Sentiment: Raised Q3 revenue outlook: Profound Medical increased its third-quarter 2026 revenue outlook to a level above Wall Street expectations. The update helped drive a 21.7% share-price surge in the prior session and suggests stronger near-term commercial momentum for the TULSA-PRO platform. Profound Medical raises Q3 2026 revenue outlook above estimates
• Positive Sentiment: Telix co-education agreement: Profound and Telix Pharmaceuticals (ASX: TLX; NASDAQ: TLX) will educate urologists, radiologists, nuclear-medicine specialists and prostate-cancer centers on combining Telix’s PSMA-PET imaging products, Gozellix and Illuccix, with Profound’s MRI-guided, AI-powered TULSA-PRO treatment. The agreement could expand Profound’s access to urologists, support evidence-based patient selection and strengthen adoption of its prostate-treatment system. No financial terms were disclosed. Profound Medical and Telix Pharmaceuticals enter co-education agreement
• Neutral Sentiment: Analyst momentum remains uncertain: Coverage highlighted the improved revenue outlook and a rating upgrade, but noted that recent earnings-estimate revisions may not translate into additional near-term gains after the stock’s substantial rally. Profound Medical Q3 revenue beats outlook
• Neutral Sentiment: Short-interest data offers little signal: Reported short interest was zero shares as of October 9, with a zero-day days-to-cover ratio. While described as an increase, the figure does not indicate meaningful short-covering pressure or a likely short squeeze.

About Profound Medical

Profound Medical Corp. NASDAQ: PROF is a medical technology company focused on developing and commercializing incisionless therapies for localized prostate disease. The company's flagship product is the TULSA-PRO system, which uses real-time magnetic resonance imaging (MRI) guidance and transurethral ultrasound to deliver controlled thermal ablation to targeted prostate tissue.

TULSA-PRO is designed to enable physicians to customize treatment based on a patient's prostate anatomy and disease location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.